Press "Enter" to skip to content

Cancer Vaccine Gets Tested On Dogs…Humans Next!

Cancer specialists today would consider vaccines for tumors as illogical. While the idea may seem far-fetched, it is known that cancer develops based on their molecular level. Johnson, however, stated that such a vaccine would have potential. Johnston works at ASUCIM; he heads a study that had provided dogs with these vaccines for preliminary rounds. If successful, a trial for humans could be underway.

Approval and cost processes made the company hesitant. However, that gave away soon enough. Canine and human cancers could be caused by environmental factors, they said. Dogs were also selected only due to their short lifespans, allowing for faster results. Johnson and Thamm launched a VACC study to find a way against cancers.

The drug trial would involve screening owners for health issues.

Then, the program dogs are selected, with one group receiving placebos and others with the actual drug. This is a perfectly viable mode, stated Dr. Lichtenfield. Thamm stated that 3 outcomes were likely. Firstly, vaccinated dogs would see fewer cancer rates. Secondly, these cancers could be delayed by a few years. Thirdly, all these options may not work after all.

Tamm stated that no dog was getting exposed to cancer via the trial. Dog owners were excited about taking part in this. PETA stated that this was similar to human subjects being tested and tracked. Thus, it didn’t find any objection. HPV vaccines and Hep B vaccines have shown maximum effectiveness so far, among cancer vaccines. Since cancer is specific to each individual, the results could vary. They are commonly therapeutic in nature and mighty expensive.

Johnston’s vaccine would prevent cancers on a grand scale and still be affordable, costing around $100-$500, which was the same for infection vaccines. 800 dogs were screened, with 80 of them having cancers. They discovered neoepitopes and used around 31 of them from hundreds to develop this vaccine. He stated that planning in advance could help prepare the immunity system for cancer response. Even if the dog trial succeeds, the team has a long battle ahead to get the product into the mainstream, after due approval.

Pedro Turner
EDITOR-IN-CHIEF At Industry News Times

Pedro leads the Science division and has a Degree in Astronomy. With an overall experience of 6 years in this industry, he manages the department and trains the employees to write the Space-related news. In addition to this, he also has few certificates to justify his role. While in free time, he spends most part of his time with his friends playing snooker and cleaning his stick.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *